Advanced Bio-Surfaces Announces New CEO

Experienced CEO is ready to drive company's commercialization

    MINNEAPOLIS, Nov. 14 /PRNewswire/ -- Advanced Bio-Surfaces, Inc., (ABS)
 announced today that David Lorenzi has joined the company as its new
 President and Chief Executive Officer. Mr. Lorenzi will also serve as a
 member of the ABS Board of Directors. The company's founder and former CEO,
 Jeffrey Felt, M.D. will serve as Chairman and Chief Technology Officer.
     Mr. Lorenzi is a seasoned executive with expertise in leading the
 commercial growth of orthopedic medical devices companies. ABS Founder, Dr.
 Jeff Felt praised David's acumen, citing his "established record of
 bringing focus to organizations and his reputation as a leader possessing
 both the experience and drive needed to lead ABS to profitability. ABS will
 benefit greatly from these qualities."
     Mr. Lorenzi's experience includes roles as President and Chief
 Executive Officer for both OMNI life science, Inc. and PLUS Orthopedics
 USA, Inc.. Both companies focus on the orthopedic segment of healthcare,
 primarily with joint reconstruction products. In addition to OMNI life
 science and PLUS Orthopedics, David has also held various field, senior and
 executive level management positions with Ethicon, Orthofix, EMPI and
 Medtronic. He has participated as a member of the Board of Directors of
 PLUS Orthopedics, Inc., OMNI life science, Inc. and Enztec, Ltd.
     "I am very excited to be part of ABS," said David Lorenzi. "The company
 has developed a pipeline of unique products that address the unmet needs of
 orthopedic surgeons and their patients. I look forward to working with Dr.
 Jeff Felt and the management team to build a strong business that achieves
 our strategic objectives and maximizes value for our shareholders."
     About Advanced Bio-Surfaces, Inc.
     ABS is a privately held company dedicated to the development of
 innovative joint restoration products. The company's first product, the
 OrthoGlide Medial Knee Implant, is intended for the treatment of patients
 with moderate osteoarthritis of the medial compartment. The company
 received 510(k) clearance to market from the U.S. Food and Drug
 Administration (FDA) and CE mark notification from its Notified Body, in
 February 2006. For additional information contact ABS at 952.912.5400 or
 visit the website at http://www.advbiosurf.com.
 
 

SOURCE Advanced Bio-Surfaces, Inc.